HS 10390
Alternative Names: HS-10390Latest Information Update: 18 Sep 2023
At a glance
- Originator Hansoh BioMedical R&D Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 23 May 2023 Phase-I clinical trials in Unspecified (In volunteers) in China (PO) (NCT05942625)